Delayed Puberty in Girls
Definition & Diagnostic Criteria
- Absence of secondary sexual characteristics (breast development/thelarche) by age 13 years.
- Absence of menarche by age 15 to 16 years.
- Absence of menarche >3 to 5 years following onset of thelarche.
- Lower age cutoff applicable if strong familial pattern of early puberty exists.
Etiological Classification
Hypogonadotropic Hypogonadism (Low/Normal FSH & LH)
Characterized by absent or diminished gonadotropin secretion from hypothalamic-pituitary axis.
Transient / Functional (Reversible)
- Constitutional Delay of Growth and Puberty (CDGP): Extreme variant of normal pubertal timing. Strong genetic basis.
- Nutritional Disorders: Malnutrition, anorexia nervosa, bulimia, undernutrition.
- Exercise-Induced: Athletic amenorrhea (excessive physical training/energy deficit).
- Systemic Chronic Illness: Renal failure, liver disease, celiac disease, inflammatory bowel disease, cystic fibrosis, thalassemia, sickle cell disease, renal tubular acidosis.
- Endocrinopathies: Hypothyroidism, hyperprolactinemia, poorly controlled Type 1 Diabetes Mellitus, Cushing syndrome.
Permanent / Isolated (Irreversible)
- Isolated Hypogonadotropic Hypogonadism (IHH) & Kallmann Syndrome: Defective GnRH synthesis, secretion, or receptor action. Anosmia/hyposmia present in Kallmann syndrome.
- Genetic Mutations: KAL1 (ANOS1), FGFR1, FGF8, PROK2, PROKR2, CHD7, GNRH1, GNRHR, KISS1, KISS1R, TAC3, TACR3.
- Multiple Pituitary Hormone Deficiencies:
- Malformations: Holoprosencephaly, septo-optic dysplasia, midline facial defects.
- Genetic: PROP1, HESX1, LHX3, SOX2 mutations.
- Acquired Central Nervous System (CNS) Lesions:
- Tumors: Craniopharyngioma, germinoma, astrocytoma, optic glioma.
- Injury: Cranial irradiation, neurosurgery, head trauma, postinfectious (meningitis, encephalitis).
- Infiltrative: Langerhans cell histiocytosis, autoimmune hypophysitis.
- Dysmorphic Syndromes: CHARGE syndrome, Prader-Willi syndrome, Laurence-Moon syndrome, Bardet-Biedl syndrome.
Hypergonadotropic Hypogonadism (Elevated FSH & LH)
Characterized by primary gonadal failure. Lack of sex steroid production eliminates negative feedback, elevating gonadotropins.
| Category | Specific Etiology | Pathophysiology & Features |
|---|---|---|
| Chromosomal | Turner Syndrome (45,X & mosaicism) | Most common cause. Short stature, webbed neck, cubitus valgus, streak gonads. |
| Gonadal Dysgenesis | 46,XY with SRY deletion (Swyer Syndrome) | XY karyotype, female phenotype, streak gonads. |
| 46,XX Gonadal Dysgenesis | FSHR mutations, Perrault syndrome (sensorineural deafness). | |
| Trisomy 13, 18, 21 | Associated severe dysmorphism and intellectual disability. | |
| Steroidogenic Defects | CYP17A1 (17α-hydroxylase deficiency) | Hypertension, hypokalemia, sexual infantilism. |
| CYP19A1 (Aromatase deficiency) | Failure of estrogen synthesis. Virilization, tall stature, delayed epiphyseal closure. | |
| StAR deficiency | Congenital lipoid adrenal hyperplasia, primary adrenal failure. | |
| Ovarian Insults | Chemotherapy / Alkylating agents | Cyclophosphamide, busulfan exposure destroys primordial follicles. |
| Pelvic / Abdominal Irradiation | Dose-dependent follicle destruction (>10-15 Gy causes acute failure). | |
| Autoimmune Oophoritis | Autoimmune polyendocrinopathy (APS). | |
| Infections | Mumps oophoritis. | |
| Metabolic | Galactosemia, Carbohydrate-deficient glycoprotein syndrome. | |
| Receptor Defects | Gonadotropin Resistance | FSHR or LHR mutations (Savage syndrome). |
Eugonadotropic / Structural Abnormalities (Isolated Amenorrhea)
Normal pubertal development (thelarche present) but absent menarche due to anatomical or androgen-receptor defects.
- Müllerian Agenesis (Mayer-Rokitansky-Küster-Hauser Syndrome): Aplasia of uterus and upper vagina. Normal ovarian function.
- Outflow Tract Obstruction: Transverse vaginal septum, imperforate hymen (presents with cyclical pain, hydrocolpos/hematocolpos).
- Complete Androgen Insensitivity Syndrome (CAIS): 46,XY karyotype. Defective androgen receptor. Female external phenotype, absent uterus, sparse pubic/axillary hair, cryptorchid testes.
Detailed Pathophysiology & Genetics
Constitutional Delay of Growth and Puberty (CDGP)
- Represents delayed maturation of hypothalamic-pituitary-gonadal (HPG) axis.
- Inherited predominantly via autosomal dominant pattern with incomplete penetrance.
- Exact neuroendocrine pathophysiology remains undiscovered in majority.
- Associated genetic mutations: IGSF10 (dysregulates GnRH neuronal migration from olfactory bulb to hypothalamus), FTO variants.
Gonadotropin-Releasing Hormone (GnRH) Deficiency
- Disruption in GnRH neuron migration or signaling pathways.
- KAL1 (ANOS1) mutation: X-linked recessive. Defective neural cell adhesion molecule. Prevents migration of GnRH neurons and olfactory neurons. Results in Kallmann syndrome (anosmia + IHH).
- KISS1 / KISS1R mutations: Loss of kisspeptin signaling (crucial physiological trigger for GnRH pulsatility) causes profound hypogonadotropic hypogonadism.
- TAC3 / TACR3 mutations: Defective neurokinin-B signaling.
Turner Syndrome (45,X)
- Accelerated apoptosis of ovarian follicles.
- Fetal ovaries contain normal oocyte numbers at midgestation, followed by drastic reduction and formation of fibrous streak gonads.
- SHOX gene haploinsufficiency causes profound short stature and skeletal anomalies (short fourth metacarpal, cubitus valgus).
Clinical Evaluation and Diagnostic Approach
History
- Growth Pattern: Review historical growth charts. CDGP exhibits deceleration in first 2 years, then normal prepubertal velocity along lower percentiles. Growth arrest suggests acquired hypothyroidism, hypercortisolism, or organic CNS lesion.
- Family History: Maternal/paternal age of pubertal onset, delayed growth spurts. Autoimmune diseases, anosmia, infertility.
- Systemic Symptoms: Headaches, visual field deficits, polyuria/polydipsia (craniopharyngioma/CNS tumor).
- Nutritional/Psychosocial: Caloric restriction, intense athletic training, psychological stress, eating disorders.
Physical Examination
- Anthropometry: Height, weight, BMI, upper-to-lower segment ratio, arm span. Eunuchoid proportions (arm span > height, low upper:lower ratio) suggest delayed epiphyseal fusion (hypogonadism).
- Pubertal Staging (Tanner): Objective assessment of breast (thelarche) and pubic hair (pubarche) development.
- Syndromic Stigmata:
- Turner Syndrome: Webbed neck, low posterior hairline, shield chest, widely spaced nipples, high-arched palate, multiple pigmented nevi.
- Prader-Willi: Hypotonia, morbid obesity, small hands/feet.
- Kallmann Syndrome: Anosmia/hyposmia, midline facial defects (cleft lip/palate).
- Genital Examination: Assess estrogenization of vaginal mucosa (thin, red, dry suggests hypoestrogenism). Rule out imperforate hymen or clitoromegaly (virilizing disorder).
- Neurological Examination: Fundoscopy, visual fields (optic glioma/craniopharyngioma), cranial nerves (olfaction).
Laboratory Investigations
Tier 1: Baseline Screening
- Bone Age Radiograph (Left Hand/Wrist): Estimates skeletal maturation. Typically delayed in CDGP, malnutrition, endocrinopathies. If bone age ≥ 11-13 years and puberty absent, hypogonadism likely.
- Gonadotropins (LH, FSH): Differentiates primary vs. secondary hypogonadism.
- Elevated FSH/LH: Primary ovarian insufficiency (hypergonadotropic).
- Low/Normal FSH/LH: CDGP or hypogonadotropic hypogonadism.
- Sex Steroids: Estradiol, Testosterone (to exclude androgen insensitivity).
- Chronic Disease Panel: Complete blood count (CBC), Erythrocyte sedimentation rate (ESR), Comprehensive metabolic panel (CMP), Celiac serology (tissue transglutaminase IgA), Urinalysis.
- Endocrine Screen: Free T4, TSH, Prolactin, IGF-1.
Tier 2: Endocrine and Genetic Profiling
- Karyotype / Chromosomal Analysis: Mandatory in all girls with elevated gonadotropins or unexplained short stature to exclude Turner syndrome (45,X) or mosaicism.
- GnRH Agonist Stimulation Test: Differentiates CDGP from persistent isolated hypogonadotropic hypogonadism. LH response >3.2-5.0 U/L indicates maturing HPG axis (CDGP).
- Inhibin B / AMH: Very low levels indicate depleted ovarian reserve.
Imaging Modalities
- Pelvic Ultrasonography: Confirms presence/absence of uterus and ovaries.
- Normal uterus + absent puberty = CDGP or Hypogonadotropic hypogonadism.
- Absent uterus = Müllerian agenesis or Complete Androgen Insensitivity.
- Streak gonads = Gonadal dysgenesis.
- Brain MRI: Indicated in hypogonadotropic hypogonadism (low FSH/LH) with associated neurological symptoms, visual defects, growth hormone deficiency, or elevated prolactin. Evaluates hypothalamus, pituitary, and olfactory bulbs.
Management and Therapeutic Strategies
Psychosocial Support and Expectant Management
- Reassurance: Primary approach for CDGP. Counsel regarding physiological variations in pubertal tempo. Reassure eventual spontaneous development and normal adult height achievement.
- Psychological Counseling: Address poor self-image, peer-group pressure, depression, and eating disorders. Optimize nutrition and reduce exercise intensity in functional hypothalamic amenorrhea.
Sex Hormone Replacement Therapy (HRT) Protocols
Indicated for irreversible primary hypogonadism (e.g., Turner syndrome, POI) or prolonged CDGP causing significant psychosocial distress.
Estrogen Induction
- Goal: Initiate secondary sexual characteristics, stimulate uterine growth, prevent osteoporosis, and optimize psychological well-being.
- Timing: Initiate between 11.0 to 12.0 years of age. Coordinate with Growth Hormone therapy in Turner syndrome to avoid compromising final adult height via premature epiphyseal fusion.
- Dosing Strategy: Begin with very low-dose estrogen. Gradually escalate every 6 months to adult replacement dose over 2.5 to 3.0 years.
- Transdermal Estradiol (Preferred, highly physiological): 14 mcg daily for 1 week/month or continuously. Escalate slowly to 50-100 mcg daily adult dose.
- Oral Micronized Estradiol: 0.25 mg daily (5 mcg/kg/day). Escalate to 1-2 mg daily.
- Oral Conjugated Estrogens: 0.15 - 0.3 mg daily. Escalate to 0.625 - 1.25 mg daily.
- IM Depot Estradiol: 0.2 mg/month. Escalate to 1.0 - 1.5 mg/month.
- Note: Oral contraceptive pills (OCPs) contain supraphysiological estrogen doses and are contraindicated for initial pubertal induction.
Progestin Addition
- Goal: Prevent unopposed estrogen stimulation, endometrial hyperplasia, and endometrial carcinoma.
- Timing: Add progestin after 12 to 24 months of continuous estrogen therapy, or immediately if breakthrough vaginal bleeding occurs.
- Dosing Strategy:
- Micronized progesterone 100-200 mg/day at bedtime for 10-14 days per month.
- Medroxyprogesterone acetate 5-10 mg/day for 10-14 days per month.
- Maintenance: Once adult dosing and full pubertal development are achieved, patients may transition to combined oral contraceptive pills (OCPs) for convenience.
Specific Condition Management
Turner Syndrome
- Growth Hormone (rhGH): Initiate early (age 4-6 years) to maximize linear growth. Dose: 0.375 mg/kg/week.
- Oxandrolone: Non-aromatizable androgen added if extreme short stature persists.
- Comorbidity Screening: Mandatory annual surveillance for autoimmune thyroiditis (Free T4, TSH), celiac disease (tTG IgA), diabetes mellitus (HbA1c), dyslipidemia, and renal/cardiac malformations (Echocardiogram, MRI).
- Auditory/ENT: High risk of recurrent otitis media, conductive and sensorineural hearing loss. Routine audiology evaluation.
Structural Outflow Tract Anomalies
- Imperforate hymen or transverse vaginal septum require prompt surgical excision/vaginoplasty to relieve hematocolpos/hydrocolpos and establish menstrual outflow.
Fertility Preservation & Future Planning
- Discuss infertility implications early in diagnosis of Primary Ovarian Insufficiency (POI) or Turner Syndrome.
- Options include oocyte cryopreservation (if residual ovarian follicles exist and patient is post-pubertal), donor oocyte in-vitro fertilization (IVF), and gestational surrogacy.
- Experimental techniques: Cryopreservation of immature ovarian tissue prior to complete follicular depletion.